A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden

Nordic Journal of Psychiatry

Volumn 65, Issue 6, 2011, Pages 403-413

  Lindström, Eva ^a   Eberhard, Jonas ^b   Fors, Björn M ^a   Hansen, Karina ^c   Sapin, Christophe ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Lundbeck   (France)

Author keywords

Antipsychotics; Cost effectiveness; Cost utility; Pharmacoeconomics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MENTAL DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; RELAPSE; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEDEN; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HALOPERIDOL; HUMANS; IMIDAZOLES; INDOLES; MALE; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PIPERAZINES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SWEDEN;

EID: 80055097521     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.590603     Document Type: Article

References (32)

1. De Hert M, Thys E, Boydens J, Gilis P, Kesteloot K, Verhaegen L, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24:519-27. (Pubitemid 28524623)
2. Fadden G, Bebbington P, Kuipers L. The burden of care: The impact of functional psychiatric illness on the patient ' s family. Br J Psychiatry 1987;150:285-92. (Pubitemid 17036633)
3. Kuipers L. Family burden in schizophrenia: Implications for services. Soc Psychiatry Psychiatr Epidemiol 1993;28:207-10.
4. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9. (Pubitemid 41442278)
5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23. (Pubitemid 41345943)
6. Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59:31-7.
7. Grohmann R, Ruther E, Schmidt LG. Unerwunschte Wirkungen von Psychopharmaka. Ergebnisse de AMUP-Studie. Berlin: Springer; 1994.
8. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-38. (Pubitemid 24013155)
10. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: An unavoidable fact of life. Health Econ 1997;6:217-27. (Pubitemid 27296586)
11. Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006;21:49-56. (Pubitemid 43175123)
12. S ong F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating effi cacy of competing interventions: Empirical evidence from published meta-analyses. BMJ 2003;326: 472.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.
14. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997;154:782-91. (Pubitemid 27230100)
15. H ale A, Azorin J-M, Kasper S, Maier W, Syvalahti E, Van Der Burght M, et al. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial. Int J Psychiatr Clin Pract 2000;4:47-54. (Pubitemid 30198336)
16. Abbott Laboratories. Abbott Study (M92-817). Data on file 1995.
17. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90. (Pubitemid 36818630)
18. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74. (Pubitemid 32429846)
19. Bebbington PE, Angermeyer M, Azorin JM, Brugha T, Kilian R, Johnson S, et al. The European Schizophrenia Cohort (EuroSC): A naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol 2005;40:707-17. (Pubitemid 41479058)
20. Launois R, Graf von der Schulenburg M, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: A comprehensive model. Int J Psychiatr Clin Pract 1998;2:S79-86.
21. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57 Suppl 11:53-60. (Pubitemid 26389786)
22. Launois R, Almond S, Présenté G, Toumi M. Cost-effectiveness of sertindole versus risperidone, olanzapine or haloperidol: A comprehensive model, sertindole NICE submission 2001. 2001.
23. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term effi cacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998;34:61-9. (Pubitemid 28176303)
24. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006;189:433-40. (Pubitemid 44683176)
25. De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: A Belgian costeffectiveness analysis. Pharmacoeconomics 2005;23 Suppl 1:35-47.
26. Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study. Curr Med Res Opin 2006;22: 2209-19. (Pubitemid 44789986)
27. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006:CD004578.
28. Revicki DA. Cost effectiveness of the newer atypical antipsychotics: A review of the pharmacoeconomic research evidence. Curr Opin Investig Drugs 2001;2:110-7. (Pubitemid 32094012)
29. Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl 1:49-61.
30. Llorca PM, Miadi-Fargier H, Lancon C, Jasso Mosqueda G, Casadebaig F, Philippe A, et al. [Cost-effectiveness analysis of schizophrenic patient care settings: Impact of an atypical antipsychotic under long-acting injection formulation]. Encephale 2005;31: 235-46. (Pubitemid 40684456)
31. Almond S, O' Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17:383-9. (Pubitemid 30236173)
32. Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P. Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. J Med Assoc Thai 2005;88:1267-77. (Pubitemid 43154727)